Select Characteristics of Adults Living with HIV in New York State



Medical Monitoring Project Data, 2018 - 2022

The Medical Monitoring Project (MMP) is an ongoing, locally, and nationally representative surveillance system funded by the Centers for Disease Control and Prevention. The MMP survey collects data on a probability sample of adults with diagnosed HIV across the United States, inclusive of state and city health departments. Between 2018 and 2022, 1,926 individuals living with HIV participated in MMP in New York State (including New York City).

Demographic Characteristics


- 70% were cisgender male, 28% were cisgender female, and 2% were transgender.[†]
- 43% were Black/African American, 31% were Hispanic/Latino, and 21% were White.
- 50% had a household income at or below the federal poverty level.
- 15% were unstably housed or homeless during the 12 months before interview.


Antiretroviral Therapy and Viral Suppression

	Antiretroviral Therapy*		Viral Suppression*
Characteristic	Prescription 12 months before interview	100% dose adherence 30 days before interview	Sustainability ¹ 12 months before interview
Overall	84%	60%	62%
18–29 years	79%	38%	54%
30–39 years	77%	56%	59%
40-49 years	87%	49%	58%
≥50 years	85%	66%	64%
Black/African American	83%	59%	61%
Hispanic/Latino [‡]	85%	60%	59%
White	84%	63%	70%
Cisgender male	83%	60%	62%
Cisgender female	85%	62%	62%
Transgender [†]	82%	49%	64%

Median stigma score**

Based on four dimensions: personal, disclosure, self-image, and public attitudes. Range from 0 (no stigma) to 100 (high stigma).





Note: Percentages are weighted. Percentages might not sum to 100 because of rounding.

‡ Hispanic or Latino individuals can be of any race. Persons are classified in only one race/ethnicity category.

+Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose transgender in response to the question about selfidentified gender.

*Prescribed antiretroviral therapy, antiretroviral therapy dose adherent, and sustained viral suppression are mutually exclusive categories due to variation in the time periods assessed. **"Median HIV stigma score" defined as the weighted median score on a 10-item scale. The HIV stigma scale used for this indicator is available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001277/table/T1/?report=objectonly

Questions, contact us: New York State Department of Health Bureau of HIV/AIDS Epidemiology

bhae@health.ny.gov

For more information about MMP, visit: https://www.cdc.gov/hiv-data/mmp/



https://www.health.ny.gov/diseases/aids/general/statistics/